AUA 2021 Bladder Cancer

Viewing 1-20 of 27 articles

AUA 2021: Pre-Surgical Multiparametric Magnetic Resonance Imaging Features Predicting Continence After Robotic Radical Cystectomy With Orthotopic Bladder Reconstruction: Preliminary Findings Form PURE-01 Trial

AUA 2021: Utility of Blue Light Flexible Cystoscopy for Bladder Cancer Surveillance after Intravesical Therapy

AUA 2021: Intravesical Therapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis of Oncologic Outcomes

AUA 2021: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial: Subgroup Analysis by Duration of Treatment-Free Interval from End of Chemotherapy to Start of Maintenance

AUA 2021: Long-Term Recurrence Free Survival Following UGN-101 Treatment for Low-Grade Upper Tract Urothelial Carcinoma

AUA 2021: Female Patients With Low-Grade Upper Tract Urothelial Carcinoma: Primary Chemoablation and Durability of Response in a Subgroup Analysis From the OLYMPUS Trial

AUA 2021: Perioperative Intravesical Chemotherapy in Minimally Invasive Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Low but Increasing Utilization Worldwide

AUA 2021: Novel Weekly Immunotherapy Dosing with Avelumab Tolerated During Bacillus Calmette-Guerin Induction Therapy: Initial Results of the ABC Trial

AUA 2021: Initial Results from a Phase 1/2 Trial of Large Surface Area Microparticle Docetaxel for High-Risk Non-Muscle Invasive Bladder Cancer

AUA 2021: Updated Treatment Results from a Phase I study of WST11 Phototherapy (VTP) for Upper Tract Urothelial Carcinoma

AUA 2021: Bladder Cancer: What is New in Biomarkers?

AUA 2021: A Urine-Based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Pilot Study

AUA 2021: Individualized Mutation Detection in Plasma and Urinary Circulating Tumor DNA for Monitoring Upper Tract Urothelial Carcinoma Using Digital Polymerase Chain Reaction

AUA 2021: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Analysis of Clinical and Genomic Subgroups From the JAVELIN Bladder 100 Trial

AUA 2021: Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (OPTIMA II): A Phase 2b, Open-Label, Single-Arm Trial

AUA 2021: Avelumab First-Line Maintenance Plus Best Supportive Care vs Best Supportive Care Alone for Advanced Urothelial Carcinoma: Analysis of Time to End of Next-Line Therapy in JAVELIN Bladder 100

AUA 2021: Quality of Life After Cystectomy and Urinary Diversions

AUA 2021: The Future of Neoadjuvant Therapy in Bladder Cancer

AUA 2021: Ramon Guiteras Lecture: Three Decades of Bladder Cancer Treatment: Progress and Promise

AUA 2021: AUA Guideline Amendment: Non-Muscle Invasive Bladder Cancer/Muscle Invasive Bladder Cancer

1
2